So proud-brilliant scientists Dana Orange, Ezgi Hacisuleyman, and Rizwana Qadri & Krithi Irmady, highlighted Rockefeller University with beautiful papers on Rheumatoid Arthritis, memory mechanisms & Parkinson's Disease-next to the amazing Svetlana Mosjov! Science, Present & Future=Female

I was reading 2023 Nobel laureate Katalin Kariko's book, Breaking Through. She was brutally honest about the academic system in US. And, here is an example section from her book.

7504 (Luciano J Costa): Cilta-cel subgroup analysis. Interesting that both arms performed relatively similarly in the functional high-risk cohort as in all comers in 2L. Cilta-cel seems like a great option for these patients though longer f/u will be important

7505 (Arnulf): Cilta-cel cohort 2D in newly diagnosed (n=17). Median age 54 and only 1 pt had HRCA. 12 pts MRD <10^-5. 94% PFS and OS at 18-months. CRS in 82% (all G1). No parkinsonism. 1 secondary MDS. Brings excitement to the CARTITUDE-6 study comparing cilta-cel vs ASCT!

There's still time to register for the 2024 Tri-I Breakout Prize for Junior Investigators! The Scientific Symposium will be held on Friday, June 14th, 10:30AM @ the Belfer Research Building. rb.gy/lyrwwi @arif_uzz_aman Naama Aviram @Ale_Brambati

1. Donate cord blood - it can #SaveALife 2, But, hoarding #CordBlood for self-use is rarely beneficial (thankfully) and usually wasted (sad). #CordBloodDonation nytimes.com/2024/07/15/hea…

Having spent my medical school years inspired by Dr R Balasubramaniam ‘s selfless and single minded efforts to bring healthcare and a good QOL to some of the most denied but deserving, this is a proud moment. Amazing!!!

#IMS24 updated PROs from CARTITUDE-4 remain as stunning as ever to support CAR-T in earlier lines 👏 Pain scores vary widely (although consistently better in CAR-T treated)… But look at how quickly and durably patient fatigue improves with CAR-T vs pom-dex triplet forever!

For US #HCPs at #IMS24: watch Dr. María-Victoria Mateos present updated results at ~3 years follow-up, including overall survival analysis, from the Phase 3 CARTITUDE-4 study of BCMA CAR-T therapy in patients with relapsed & lenalidomide-refractory #MultipleMyeloma.

#IMS24 marivi mateos reveals what we’ve all heard in passing - an OS benefit with cilta-cel in CARTITUDE-4! BCMA CAR-T now officially can improve overall survival vs DPd/PVd in myeloma #MMsm 🎉 Improvement in PFS, OS, *and* in PROs - the trifecta we’ve all been looking for!

Hotel internet connections are frustrating!

can’t make this up 😭😭

Astoria the Wild Turkey relaxes in a tree on a warm autumn day on Roosevelt Island. 🦃 ❤️ #birdcpp

So inspiring every time Jedd Wolchok

Pretty neat Ash Tewari, MD

Pretty neat Bob Darnell (@darnelr.bsky. & bob.darnell@Threads) lab... nytimes.com/2025/02/18/sci…

Today's cover: MTA greenlights $250M for consultants to expand Second Avenue subway — at expected cost of $4.3B per mile to build trib.al/UFOY4Nq

What happens when a cancer researcher becomes a patient herself—and then sets out to change the future of myeloma care? 👩‍🔬 Our Chief Medical Officer Dr. Gwen Nichols sat down with Urvi Shah for a conversation you don’t want to miss 👉 bit.ly/4c5Zx90

“The most effective way to prevent the spread of measles is the MMR vaccine.” Important message from Secretary Kennedy. Completely agree and encourage all parents to make sure their children are vaccinated against measles.

Photo of the year for myeloma: Cilta-cel in multi-drug refractory disease From Jagannath, Plasma Cell Pete et al Journal of Clinical Oncology #ASCO25